Ert Pompe denied as not FDA-approved for this use by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for ert pompe are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies ERT for Pompe Disease as Not FDA-Approved

A "not FDA-approved" denial for an enzyme replacement therapy used in Pompe disease is almost always an administrative coding or policy-lookup error. It may arise because: (1) a newer ERT agent was recently approved and the plan's policy database has not been updated; (2) the billing code submitted does not match the drug name in the plan's approval table; or (3) the drug was prescribed for a patient subgroup the plan's policy has not yet recognized under the approved indication, even though the FDA label covers it.

This type of denial is among the most straightforwardly overturned — the FDA approval record is a matter of public record.

## Why This Denial Is Appealable

FDA approval is a federal determination that a plan cannot override with an internal policy. If the prescribed ERT holds a current FDA approval for Pompe disease (or for the patient's specific disease subtype), the "not FDA-approved" basis for denial is factually incorrect. You are entitled to have the plan correct this error. Submit the FDA label as Exhibit A.

## Federal Appeal Framework

• ERISA §503 requires the plan to provide the specific clinical or policy rationale for the denial and to conduct a full-and-fair internal review. A factually incorrect denial reason is particularly strong grounds for reversal.
• ACA §2719 entitles you to independent external review. An IRO reviewing a "not FDA-approved" denial will check the FDA's own approval database — if the drug is approved, the denial will be overturned.
• The external-review window is generally within approximately four months of denial; confirm the exact date on your Explanation of Benefits.
• Expedited review is available and appropriate given Pompe disease's irreversible progressive course.

## Concrete Appeal Steps

1. Go to the FDA's online Drugs@FDA database and print or save the current approval record and labeling for the prescribed ERT, confirming the indication. 2. Confirm the NDC or HCPCS billing code used on the claim matches the approved product. 3. File an internal appeal with the FDA label as the primary exhibit. 4. Request that the plan identify the specific policy or database it relied upon when stating the drug is not approved — this often exposes the administrative error immediately. 5. If not resolved internally, proceed to external review.

## Documentation to Gather

• FDA label and approval record: Current prescribing information downloaded from Drugs@FDA; the approval letter or package insert showing the indication.
• Diagnosis confirmation: Genetic report and enzyme assay confirming the patient's diagnosis falls within the approved indication.
• Prescriber letter: Statement from the prescribing physician confirming the drug is being used within its FDA-approved indication for this patient's confirmed diagnosis.
• Billing records: Itemized claim showing the NDC/HCPCS code submitted, so the plan can verify the code-to-drug mapping.
• Plan policy: A copy of UHC's coverage policy for this drug — to identify whether the policy itself contains an outdated approval status that needs to be challenged.

## Criteria-Mapping Structure

For this denial type, the mapping is straightforward:

| Plan's Stated Basis | Your Rebuttal Evidence | |---|---| | Drug is not FDA-approved | FDA label dated [approval date], indication: [Pompe disease / acid alpha-glucosidase deficiency] | | Indication mismatch (if claimed) | FDA label indication section matches confirmed diagnosis per genetic and enzyme reports | | Billing code error (if applicable) | Pharmacy or infusion center confirmation of correct NDC/HCPCS code |

Lead your appeal letter with this table. The factual clarity of the rebuttal is your strongest asset.